Annexon (ANNX) Stock Price, News & Analysis

Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $2.21 to $2.32
• 50-Day Range: $2.14 to $2.96
• 52-Week Range: $1.28 to $7.85
• Volume: 540,643 shs
• Average Volume: 1.55 million shs
• Market Capitalization: $243.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Moderate Buy

Annexon Stock Analysis - MarketRank™

Annexon scored higher than 59% of companies evaluated by MarketBeat, and ranked 412th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Annexon has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Annexon has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annexon is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annexon is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annexon has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.94% of the float of Annexon has been sold short.

Short Interest Ratio / Days to Cover

Annexon has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Annexon has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annexon does not currently pay a dividend.

Dividend Growth

Annexon does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.94% of the float of Annexon has been sold short.

Short Interest Ratio / Days to Cover

Annexon has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Annexon has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.90

News Sentiment

Annexon has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Annexon this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Annexon insiders have bought 25.96% more of their company's stock than they have sold. Specifically, they have bought $20,122.00 in company stock and sold $15,975.00 in company stock.

Percentage Held by Insiders

12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANNX Stock Analysis - Frequently Asked Questions

How have ANNX shares performed this year?

Annexon's stock was trading at $5.13 on January 1st, 2025. Since then, ANNX shares have decreased by 56.4% and is now trading at $2.2350.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02.

When did Annexon IPO?

Annexon (ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO.

Who are Annexon's major shareholders?

Top institutional shareholders of Annexon include Sio Capital Management LLC (3.73%), TFG Asset Management GP Ltd (2.56%), Geode Capital Management LLC (2.08%) and Ameriprise Financial Inc. (1.97%). Insiders that own company stock include Muneer A Satter, Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, Ted Yednock, Dean Richard Artis, William H Carson and Jamie Dananberg.
View institutional ownership trends.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/25/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANNX
• CIK: 1528115
• Web: www.annexonbio.com
• Phone: 650-822-5500
• Fax: 650-636-9773
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Annexon: $12.50
• High Price Target: $14.00
• Low Price Target: $11.00
• Potential Upside/Downside: +459.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$138.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.04%
• Return on Assets: -57.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.67
• Quick Ratio: 5.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.75 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 109,890,000
• Free Float: 95,964,000
• Market Cap: $245.60 million
• Optionable: Optionable
• Beta: 1.30